| Estimate (95% CI) | Difference (95% CI) | P-value | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Standard group iDose (A) | RPP group 50Â keV (B) | RPP group DL-iodine boosting (C) | (A) vs. (B) | (A) vs. (C) | (A) vs. | |||||
(B) | (C) | |||||||||
Arterial phase | ||||||||||
All FLLs (n = 62) | 2.21 (1.24, 3.18) | 2.49 (2.14, 2.84) | 2.05 (1.80, 2.31) | 0.28 (− 0.75, 1.31) | −0.16 (− 1.16, 0.84) | 0.596 | 0.757 | |||
< 20 mm (n = 50) | 2.13 (1.15, 3.10) | 2.15 (2.02, 2.28) | 1.85 (1.66, 2.04) | 0.02 (− 0.97, 1.00) | −0.28 (− 1.27, 0.72) | 0.971 | 0.586 | |||
≥ 20 mm (n = 12) | 2.75 (1.88, 3.62) | 3.32 (2.79, 3.85) | 2.54 (1.97, 3.10) | 0.57 (− 0.44, 1.59) | −0.21 (− 1.25, 0.82) | 0.269 | 0.685 | |||
Portal venous phase | ||||||||||
All FLLs (n = 62) | 2.19 (1.34, 3.04) | 2.56 (2.04, 3.08) | 2.32 (1.87, 2.77) | 0.37 (− 0.62, 1.37) | 0.13 (− 0.83, 1.09) | 0.464 | 0.787 | |||
< 20 mm (n = 50) | 2.13 (1.29, 2.96) | 2.19 (2.09, 2.29) | 1.91 (1.71, 2.12) | 0.06 (− 0.78, 0.90) | −0.22 (− 1.08, 0.64) | 0.884 | 0.621 | |||
≥ 20 mm (n = 12) | 2.60 (1.68, 3.52) | 3.46 (2.12, 4.81) | 3.32 (2.35, 4.29) | 0.86 (− 0.76, 2.49) | 0.72 (− 0.61, 2.06) | 0.298 | 0.290 |